+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Wilms Tumor Protein"

Wilms Tumor Protein Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Thumbnail Image

Wilms Tumor Protein Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • February 2024
  • 86 Pages
  • Global
From
Cancer Testis Antigen 1 - Pipeline Review, H2 2019 - Product Thumbnail Image

Cancer Testis Antigen 1 - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 76 Pages
  • Global
From
Wilms Tumor Protein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Wilms Tumor Protein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 45 Pages
  • Global
From
Cells Expressing Wilms Tumor Protein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cells Expressing Wilms Tumor Protein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 57 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

The Wilms Tumor Protein (WT1) is a protein that is expressed in Wilms tumors, a type of cancer that affects the kidneys. WT1 is a promising target for the development of oncology drugs, as it is involved in the regulation of cell growth and differentiation. WT1-targeted therapies have the potential to be used in combination with other treatments, such as chemotherapy and radiation, to improve outcomes for patients with Wilms tumors. Several companies are developing WT1-targeted therapies for the treatment of Wilms tumors. These include Novartis, which is developing a WT1-targeted antibody-drug conjugate, and Merck, which is developing a WT1-targeted small molecule. Other companies, such as AstraZeneca and Pfizer, are also researching WT1-targeted therapies. Show Less Read more